Search alternatives:
ppm decrease » _ decrease (Expand Search), pa decreased (Expand Search), 026 decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
we decrease » _ decrease (Expand Search), mean decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
50 ppm » 5 ppm (Expand Search)
50 nn » 50 ns (Expand Search), 50 ng (Expand Search), 50 n (Expand Search)
ppm decrease » _ decrease (Expand Search), pa decreased (Expand Search), 026 decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
we decrease » _ decrease (Expand Search), mean decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
50 ppm » 5 ppm (Expand Search)
50 nn » 50 ns (Expand Search), 50 ng (Expand Search), 50 n (Expand Search)
-
141
-
142
-
143
-
144
PPM1A facilitates both nuclear distribution and transcription potency of YAP/TAZ.
Published 2021“…<b>(B–D)</b> Transcription potency of YAP (5 ng), which was suppressed by coexpression of MST1 (50 ng) (B), LATS1 (500 ng) (C), or MAP4K1 (50 ng) (D), was markedly recovered by cotransfection of wild-type PPM1A but not the enzyme-dead PPM1A (D239N). …”
-
145
-
146
-
147
-
148
-
149
-
150
-
151
-
152
-
153
-
154
-
155
Image4_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg
Published 2024“…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”
-
156
Image2_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg
Published 2024“…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”
-
157
Image6_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg
Published 2024“…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”
-
158
Image1_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg
Published 2024“…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”
-
159
Image3_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg
Published 2024“…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”
-
160
Image7_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg
Published 2024“…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”